Haemonetics (HAE) Stock Price, News & Analysis

Company Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $70.25 to $72.25
• 50-Day Range: $72.00 to $80.34
• 52-Week Range: $70.25 to $97.97
• Volume: 482,264 shs
• Average Volume: 537,132 shs
• Market Capitalization: $3.64 billion
• P/E Ratio: 31.91
• Dividend Yield: N/A
• Price Target: $106.14
• Consensus Rating: Moderate Buy

Haemonetics Stock Analysis - MarketRank™

Haemonetics scored higher than 97% of companies evaluated by MarketBeat, and ranked 45th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Haemonetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.88%

Earnings Growth

Earnings for Haemonetics are expected to grow by 14.88% in the coming year, from $4.57 to $5.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Haemonetics is 31.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.07.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haemonetics is 31.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.66.

Price to Earnings Growth Ratio

Haemonetics has a PEG Ratio of 1.16. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haemonetics has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.39% of the float of Haemonetics has been sold short.

Short Interest Ratio / Days to Cover

Haemonetics has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Haemonetics has recently decreased by 2.95%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Haemonetics does not currently pay a dividend.

Dividend Growth

Haemonetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.54

Percentage of Shares Shorted

10.39% of the float of Haemonetics has been sold short.

Short Interest Ratio / Days to Cover

Haemonetics has a short interest ratio ("days to cover") of 9.

Change versus previous month

Short interest in Haemonetics has recently decreased by 2.95%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.80

News Sentiment

Haemonetics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Haemonetics this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Haemonetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Haemonetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Haemonetics is held by insiders.

Percentage Held by Institutions

99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HAE Stock Analysis - Frequently Asked Questions

How have HAE shares performed this year?

Haemonetics' stock was trading at $85.51 at the beginning of the year. Since then, HAE shares have decreased by 16.8% and is now trading at $71.15.
View the best growth stocks for 2024 here.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its quarterly earnings results on Thursday, August, 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by $0.01. Haemonetics's revenue for the quarter was up 8.0% on a year-over-year basis.

Who are Haemonetics' major shareholders?

Haemonetics' top institutional investors include Boston Trust Walden Corp (1.59%), Allspring Global Investments Holdings LLC (1.56%), Principal Financial Group Inc. (0.30%) and F M Investments LLC (0.20%). Insiders that own company stock include Christopher Simon, Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong, Laurie A Miller and Dan Goldstein.
View institutional ownership trends.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 10/31/2024
• Next Earnings (Confirmed): 11/07/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Supplies
• Current Symbol: NYSE:HAE
• CUSIP: 40502410
• CIK: 313143
• Web: www.haemonetics.com
• Phone: (781) 848-7100
• Fax: 781-848-5106
• Employees: 3,657
• Year Founded: 1971

Price Target and Rating

• Average Stock Price Target: $106.14
• High Stock Price Target: $125.00
• Low Stock Price Target: $85.00
• Potential Upside/Downside: +49.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.23
• Trailing P/E Ratio: 31.91
• Forward P/E Ratio: 15.57
• P/E Growth: 1.16
• Net Income: $117.56 million
• Net Margins: 8.61%
• Pretax Margin: 11.02%
• Return on Equity: 21.86%
• Return on Assets: 9.04%

Debt

• Debt-to-Equity Ratio: 1.35
• Current Ratio: 3.76
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: $1.33 billion
• Price / Sales: 2.73
• Cash Flow: $5.78 per share
• Price / Cash Flow: 12.31
• Book Value: $18.90 per share
• Price / Book: 3.76

Miscellaneous

• Outstanding Shares: 51,178,000
• Free Float: 50,257,000
• Market Cap: $3.64 billion
• Optionable: Optionable
• Beta: 0.30